Teva Pharmaceutical Industries Limited (TEVA) Announces $0.09 Quarterly Dividend

Teva Pharmaceutical Industries Limited (NYSE:TEVA) declared a quarterly dividend on Thursday, November 2nd, RTT News reports. Stockholders of record on Tuesday, November 28th will be paid a dividend of 0.085 per share on Tuesday, December 12th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.26%. The ex-dividend date of this dividend is Monday, November 27th.

Teva Pharmaceutical Industries has raised its dividend by an average of 2.1% per year over the last three years. Teva Pharmaceutical Industries has a dividend payout ratio of 7.6% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Teva Pharmaceutical Industries to earn $2.84 per share next year, which means the company should continue to be able to cover its $0.29 annual dividend with an expected future payout ratio of 10.2%.

Teva Pharmaceutical Industries (NYSE TEVA) opened at $15.05 on Tuesday. Teva Pharmaceutical Industries has a twelve month low of $10.85 and a twelve month high of $38.31. The stock has a market cap of $15,504.16, a PE ratio of 3.52 and a beta of 0.55. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20.

Several research analysts recently weighed in on the stock. Credit Suisse Group restated an “underperform” rating and set a $8.00 price target (down from $14.00) on shares of Teva Pharmaceutical Industries in a report on Monday, November 6th. Royal Bank Of Canada cut their price target on shares of Teva Pharmaceutical Industries from $21.00 to $15.00 and set an “underperform” rating on the stock in a report on Monday, September 18th. Wells Fargo & Company restated a “market perform” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, October 5th. Oppenheimer restated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Sunday, November 12th. Finally, BTIG Research set a $16.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Tuesday, November 28th. Seven equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $21.65.

COPYRIGHT VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Dividend History for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with's FREE daily email newsletter.

Leave a Reply